Cargando…
Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration
There have been great advances in the therapy of cancer and leukemia. However, there are still many neoplastic diseases that are difficult to treat. For example, it is often difficult to find effective therapies for aggressive cancer and leukemia. An NF-κB inhibitor named dehydroxymethylepoxyquinomi...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cognizant Communication Corporation
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751220/ https://www.ncbi.nlm.nih.gov/pubmed/32576339 http://dx.doi.org/10.3727/096504020X15929100013698 |